ResMed Inc. (RMD) Shares Bought by YorkBridge Wealth Partners LLC
YorkBridge Wealth Partners LLC grew its position in ResMed Inc. (NYSE:RMD) by 4.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,476 shares of the medical equipment provider’s stock after acquiring an additional 69 shares during the period. YorkBridge Wealth Partners LLC’s holdings in ResMed were worth $115,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of ResMed by 17.3% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 42,898 shares of the medical equipment provider’s stock worth $3,340,000 after acquiring an additional 6,316 shares in the last quarter. Delta Lloyd Asset Management N.V. bought a new stake in ResMed during the 2nd quarter worth approximately $6,194,000. Geode Capital Management LLC grew its position in ResMed by 5.5% during the 1st quarter. Geode Capital Management LLC now owns 1,176,810 shares of the medical equipment provider’s stock worth $84,667,000 after acquiring an additional 61,478 shares during the last quarter. Prudential Financial Inc. grew its position in ResMed by 50.5% during the 2nd quarter. Prudential Financial Inc. now owns 131,997 shares of the medical equipment provider’s stock worth $10,279,000 after acquiring an additional 44,266 shares during the last quarter. Finally, Achmea Investment Management B.V. acquired a new stake in ResMed during the 1st quarter valued at $785,000. Institutional investors own 60.10% of the company’s stock.
ResMed Inc. (NYSE RMD) remained flat at $76.96 during midday trading on Monday. 28,404 shares of the company’s stock traded hands. ResMed Inc. has a 52-week low of $56.59 and a 52-week high of $81.87. The stock’s 50-day moving average price is $75.91 and its 200-day moving average price is $73.47. The firm has a market capitalization of $10.94 billion, a PE ratio of 32.07 and a beta of 0.77.
ResMed (NYSE:RMD) last announced its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.02. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The company had revenue of $556.69 million during the quarter, compared to the consensus estimate of $557.68 million. During the same period in the prior year, the business earned $0.74 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. Analysts forecast that ResMed Inc. will post $3.05 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 21st. Investors of record on Thursday, August 17th were issued a dividend of $0.35 per share. This is an increase from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $1.40 annualized dividend and a dividend yield of 1.82%. ResMed’s dividend payout ratio (DPR) is 58.09%.
In other news, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $77.49, for a total transaction of $96,862.50. Following the sale, the chief financial officer now directly owns 59,258 shares of the company’s stock, valued at $4,591,902.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Hollingshead sold 7,140 shares of ResMed stock in a transaction dated Friday, July 14th. The shares were sold at an average price of $77.43, for a total value of $552,850.20. The disclosure for this sale can be found here. Insiders have sold a total of 106,758 shares of company stock worth $8,065,873 in the last 90 days. 1.77% of the stock is currently owned by corporate insiders.
Several equities analysts have issued reports on RMD shares. BMO Capital Markets lifted their price objective on ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research report on Wednesday, August 2nd. Needham & Company LLC restated a “sell” rating on shares of ResMed in a report on Wednesday, August 2nd. Zacks Investment Research cut ResMed from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Credit Suisse Group lowered ResMed from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Barclays PLC raised their target price on ResMed from $65.00 to $68.00 and gave the company an “underweight” rating in a research note on Monday, September 25th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $68.50.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.